IGM
AMRI

Incline Global Management’s Albany Molecular Research Inc AMRI Stock Holding History

Incline Global Management’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-268,000
Closed -$4.72M – 31
2015
Q1 		$4.72M Sell
268,000
-712,804
-73% -$12.1M 1.17% 25
2014
Q4 		$16M Buy
980,804
+464,881
+90% +$8.53M 4.72% 4
2014
Q3 		$11.4M Buy
+515,923
New +$10.6M 3.41% 10

Other funds holding AMRI

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
OWP
Obermeyer Wealth Partners Aspen, Colorado $2.17B AUM 19.33% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Incline Global Management's AMRI Position: Q2 2015 in Review

Incline Global Management sold out of Albany Molecular Research Inc (AMRI) in Q2 2015, closing a stake of 268,000 shares — an estimated $4.72M sold.

Incline Global Management first reported a position in AMRI in Q3 2014 and held it in 3 quarters. The position peaked at $16M in Q4 2014. 131 funds tracked by Wall St. Rank hold AMRI as of Q2 2015.

  • Incline Global Management reported no remaining Albany Molecular Research Inc position as of Q2 2015 after selling out during the quarter.
  • Incline Global Management sold 268,000 Albany Molecular Research Inc shares in Q2 2015, an estimated $4.72M.
  • Incline Global Management first reported a position in Albany Molecular Research Inc in Q3 2014 and held it in 3 quarters.
  • Incline Global Management's Albany Molecular Research Inc position peaked at $16M in Q4 2014.
  • 131 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q2 2015.

Based on Incline Global Management's 13F filing for Q2 2015, filed 14 Aug 2015.